DRUG NAME INDICATION
ADMINISTRATION
 Is indicated for booster
TETANUS injection only for persons
TOXOID 7 years of age or older
against tetanus (tetanus
toxoid).
 Primary immunization
schedule for children
under 7 years of age (prior
to seventh birthday)
should consist of five
doses of a vaccine
containing tetanus toxoid
(tetanus (tetanus toxoid)
toxoid).
 This vaccine is NOT
indicated for primary
immunization.
 For the prevention of
neonatal tetanus (tetanus
toxoid) in unvaccinated
pregnant women
 This vaccine is NOT
to be used for the
treatment of tetanus
(tetanus toxoid) infection
 As with any
vaccine, vaccination with
Tetanus Toxoid (tetanus
(tetanus toxoid) toxoid)
may not protect 100% of
susceptible individuals.
SOURCE:
DOSAGE &
 SHAKE VIAL WELL
before withdrawing each
dose.
 Inject intramuscularly or
subcutaneously in the area of
the vastus lateralis
(lateral mid-thigh) or deltoid.
 Should not be injected
into the gluteal area or areas
where there may be a
major nerve trunk.
 A needle length ≥ one
inch is preferred for these age
groups because needles less
than one inch might be of
insufficient length to
penetrate
muscle tissue in certain adults
and older children.
 Booster dose of 0.5 mL
of Tetanus Toxoid (tetanus
(tetanus toxoid) toxoid)
should be given
intramuscularly every 10
years to maintain
adequate immunity.  use.
HOW SUPPLIED
Vial, 7.5 mL Product No.
49281-812-84
STORAGE
Store between 2° -8°C (35°
-46°F). DO NOT FREEZE.
CONTRADICTIONS SIDE EFFECT NURSING
RESPONSIBILITIES
 Hypersensitivity to BODY SYSTEM AS A
any component of the WHOLE
vaccine.
 Contraindication to redness, warmth, edema,
induration with or
use this or any other
without tenderness as
related vaccine after a
well as urticaria, and
serious adverse event
rash. Malaise, transient
temporally associated
fever, pain, hypotension,
with a previous dose
nausea and arthralgia
including an
may develop in some
anaphylactic reaction.
patients after the
 Elective injection. Arthus-type
immunization
hypersensitivity
procedures should be
reactions, charac -
deferred during an terized by severe local
outbreak of reactions (generally
poliomyelitis. starting 2 to 8 hours
 A history of after an injection) may
systemic allergic or occur, particularly in
neurologic reactions persons who have
following a previous received multiple prior
dose of Tetanus (tetanus boosters.
toxoid) Toxoid is an
absolute contra -
indication for further
 A minor afebrile
illness such as a mild
upper respiratory
infection should not
preclude immunization.
MAGNESIUM  For Acute nephritis (ADULTS)  It is contraindicated  CNS: Weakness,  Reserve IV use in
SULFATE (children)  Parenteral nutrition: 8-24 with allergy to Dizziness, fainting, eclampsia for immediate
 to control mEq/day IV magnesium products; sweating (PO) life threatening
hypertension  Mild Magnesium heartblock, myocardial  CV: Palpitations situations.
 For Hypomagnesemia Deficiency: I g IM or IV q 6 damage, abdominal pain,  GI: Excessive  Give IM route for
hr for 4 doses )32.5 mEq/24 nausea, vomiting or deep IM injection of
(replacement therapy) bowel activity, Perianal
hr other symptoms of undiluted (50%) sol’n
 For Preeclampsia/ appendicitis; acute
irritations.
eclampsia  Severe Hypomagnesemi  Metabolic: for adults; dilute to a
surgical abdomen, fecal 20% sol’n for children.
 short-term treatment a: Up to 2 mEq/kg IM within Hypermagnese mia and
impaction, intestinal and  Monitor serum
4 hr o 5 g (40 mEq)/1000 mL toxicity in patients with
for constipation. biliary duct obstruction,
D5W IV infused over 3 hr. renal failure. magnesium levels
 Evacuation of the Hepatitis.
during parenteral
colon for rectal and bowel IM  Do not give during 2 therapy.
exams hr preceding delivery
 Toxemia, eclampsia,  Monitor kneejerk
 To correct or prevent nephritis: 4-5 g of a 50
because of the risk of
reflex
hypomagnesemia magnesium toxicity to
solution of 4 hr as needed
the neonate  Do not give
 Treatment of Atypical magnesium sulfate to
ventricular IV  Use cautiously with patient with abdominal
arrhythmias(Tors ades de  1-4 g of 10-20% solution. renal imsufficiency
pain, nausea and
pointes) Do not exceed 1.5mL/min of vomiting
 Adjunctive therapy for a 10% solution. Or 4-5 g of a  Monitor bowel
the treatment of acute MI 250 mL of 5% dextrose. Do function, If diarrhea and
 Inhibition of not exceed 3mL/minute and cramping occur,
premature labor discontinue usage
 Adjunct treatment of PO
exacerbations of acute  Laxative: 10 -15 g PO
asthma. Epsom salt in glass of water

(PEDIATRICS)
 Parenteral
nutrition(infants) : 2 -10
mEq/day IV.
 Antiepileptic: 20 -40
mg/kg in a 20% solution,IM,
Repeat as needed.
 Laxative: 5 -10 g PO
Epsom salt in a glass of water
  indicated for RECOMBIVAX HB
prevention of infection  Persons from birth
caused by all known through 19 years of age: A
HEPATITIS B subtypes of hepatitis B series of 3 doses (0.5 mL
VACCINE virus.  each) given on a 0-, 1-, and 6-
Other Names:
 approved for use in month schedule. (2.1)
Engerix-B, HBV individuals of all ages.  Adolescents 11 through
vaccine, Recombivax
HB, hepatitis B vaccine,
 RECOMBIVAX HB 15 years of age: A series of
hepatitis B vaccine Dialysis Formulation is either 3 doses (0.5 mL each)
(recombinant) approved for use in given on a 0-, 1-, and 6-
predialysis and dialysis month schedule or a series of
patients 18 years of age 2 doses (1.0 mL) on a 0- and
and older. 4- to 6-month schedule). (2.1)
 Persons 20 years of age
and older: A series of 3 doses
(1.0 mL each) given on a 0-,
1-, and 6-month schedule.
(2.1)

RECOMBIVAX HB
Dialysis Formulation

 Adults on predialysis or
dialysis: A series of 3 doses
(1.0 mL each) given on a 0-,
1-, and 6-month schedule.
(2.1)

BCG